AU5188590A - Human monoclonal antibodies to human immunodeficiency virus - Google Patents
Human monoclonal antibodies to human immunodeficiency virusInfo
- Publication number
- AU5188590A AU5188590A AU51885/90A AU5188590A AU5188590A AU 5188590 A AU5188590 A AU 5188590A AU 51885/90 A AU51885/90 A AU 51885/90A AU 5188590 A AU5188590 A AU 5188590A AU 5188590 A AU5188590 A AU 5188590A
- Authority
- AU
- Australia
- Prior art keywords
- human
- monoclonal antibody
- hiv
- antibody
- directed against
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims description 69
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 108010027044 HIV Core Protein p24 Proteins 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 230000007541 cellular toxicity Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 86
- 101710205625 Capsid protein p24 Proteins 0.000 description 32
- 101710177166 Phosphoprotein Proteins 0.000 description 32
- 101710149279 Small delta antigen Proteins 0.000 description 32
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 31
- 230000009257 reactivity Effects 0.000 description 13
- 230000036436 anti-hiv Effects 0.000 description 12
- 239000011324 bead Substances 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 230000016784 immunoglobulin production Effects 0.000 description 10
- 239000002596 immunotoxin Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 208000031886 HIV Infections Diseases 0.000 description 9
- 230000002637 immunotoxin Effects 0.000 description 9
- 231100000608 immunotoxin Toxicity 0.000 description 9
- 229940051026 immunotoxin Drugs 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 6
- 238000013507 mapping Methods 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 229960002555 zidovudine Drugs 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000087624 Monoclona Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000006873 Coates reaction Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000609499 Palicourea Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101100172461 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ENV9 gene Proteins 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000003156 radioimmunoprecipitation Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 238000002333 serotherapy Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000489861 Maximus Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100040908 Putative glycerol kinase 5 Human genes 0.000 description 1
- 101710111071 Putative glycerol kinase 5 Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000007919 viral pathogenicity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Description
HUMAN MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS BACKGROUND OF THE INVENTION
The government has rights to this invention by virtu of funding from grant AI-72658 from the National Institutes o Health.
The human immunodeficiency virus (HIV) has bee implicated as the causative agent of acquired immune deficienc syndrome (AIDS). Two different serotypes of the virus ha been identified to date: HIV-1 and HIV-2. It is currentl believed that the majority of individuals that become infect with HIV eventually will develop AIDS and are likely to succu to fatal infections and/or malignancies. At this time it estimated that approximately 1.5 million individuals .have be infected by HIV in the United States alone. ,
Several avenues have been explored to treat individua afflicted with AIDS or HIV infections. The antiviral dr azidothymidine (AZT) has been found to produce both clinic and ixαmunological improvements upon short term administrati to patients afflicted with AIDS and ARC (AIDS Related Comple a ,prodrome of the disease) and to decrease the mortality ra and frequency of opportunistic infections. Although clinic benefits are achieved with AZT, it is costly. A furth drawback is that significant drug toxicity often, accompani administration of AZT. This may necessitate blood transfusio and/or reduction of the AZT dosage, or in some instance discontinuance of AZT therapy altogether. Nonetheless, AZT
the only drug currently authorized for the treatment of AIDS.
An alternative treatment that is currently under evaluation involves administration of one or more lymphokines. Interferon (particularly gamma-interferons) and interleukin-2 are currently being studied for possible use in the treatment of HIV infections. However, the preliminary results of early clinical trials are not promising. Patients receiving lym- phokine therapy often suffer serious side effects including low blood pressure, nausea and diarrhea. It has been proposed to use monoclonal antibodies of defined specificities directed against HIV proteins expressed in infected individuals as therapeutic agents. These proteins are part of the virus particles and are expressed by HIV infected cells and are designated inter alia as p24 and gp41. The identification and isolation of gp41 is described in U.S. Patent No. 4,725,669 of M. Essex, issued February 16, 1988 as is its use in the treatment and diagnosis of AIDS. The identification of p24 has been described in Allan, J.S. et al.. Science 228; 1091, 1985. However, the use of monoclonal antibodies for the treatment of HIV infections has been hampered because only a limited number of murine and rat monoclonal antibodies to HIV proteins are available. In addition, none of the currently available monoclonal antibodies directed against HIV proteins are of human origin. Administra- tion of murine antibodies to humans can cause dangerous life threatening immunologic reactions, and such antibodies may not be effective in binding to the target HIV proteins in humans.
Stable human cell lines which produce monoclonal antibodies directed against HIV would be useful for treatin and/or diagnosing individuals infected with the virus. However, human monoclonal antibodies and particularly thos directed against HIV have proven to be far more difficult t produce than those of either rat or mouse origin. Amongst th explanations for this problem are: (a) the most availabl source of lymphocytes from humans, the peripheral blood, normally contains few antibody producing cells and in som instances, none at all; (b) transformation of antibody produc
ing cells can be achieved using Epstein-Barr virus (EBV) , bu the level of antibody production by these transformed cells i often low and unstable; (c) stability of antibody productio can be enhanced, as can levels of antibody production, b fusion of EBV-transformed lines to mouse myeloma cells but these 'heterohybridomas' readily delete human chromosomes an immunoglobulin production is often lost; and (d) fusion o normal or transformed B cells to human lymphoblastoid lines o to heteromyelomas stabilizes antibody production but, unti recently, few satisfactory parent lines of this cell type hav been available.
OBJECTS OF THE INVENTION
It is an object of the present invention to provid human lymphoblastoid cell lines producing monoclonal antibodie directed against protein components of HIV.
Another object of the present invention is to provid diagnostic and therapeutic agents comprising human monoclona antibodies directed against HIV proteins which have a low non specific toxicity for use in the diagnosis and treatment of in dividuals infected with HIV.
A further object of the present invention is to provid a method for treating individuals suffering from HIV infection by administering human monoclonal antibodies directed agains protein components of HIV to said individual.
A still further object of the present invention is t provide pharmaceutical formulations for treating individual suffering from HIV infections.
These and other objects of the present invention wil be apparent to those of ordinary skill in the art in light the following specification.
SUMMARY OF THE INVENTION
The present inventors have discovered new monoclon antibodies for the treatment, prophylaxis and diagnosis human immunodeficiency virus (HIV) infections. These are hum monoclonal antibodies directed against HIV proteins gp41 a
p24 which are expressed by infected cells. The human monoclo¬ nal antibodies of the present invention may be used as diagnos¬ tic agents, directly as therapeutic agents, as the basis for vaccines or to form conjugates by covalent coupling with cytotoxic agents, specific anti-HIV drugs or radionuclides (the antibody/toxin conjugates are alternatively referred to herein as immunotoxins) for use in the diagnosis and treatment of in¬ dividuals that have been exposed to or infected with HIV. The present invention provides stable human lymphoblastoid cell lines which secrete human monoclonal antibodies directed against HIV proteins gp41 and p24. The invention also provides human monoclonal antibodies directed against HIV proteins p24 and gp41.
Another aspect of the present invention comprises a method for treating a mammal infected with HIV comprising administering to a mammal in need of such treatment an effec¬ tive amount of a human monoclonal antibody directed against HIV.
In a further aspect, the present invention comprises pharmaceutical formulations comprising an effective amount of a human monoclonal antibody to HIV proteins.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a radio-immunoprecipitation assay of 125[l]-labelled HIV lysate with serum from an HIV-infected subject or with antibodies from a subset of the human monoclonal antibody producing cell lines of the present invention.
Figure 2 is a Western blot analysis of human sera and an anti-p24 monoclonal antibody of the present invention.
Figure 3 (a-g) are graphs of the growth kinetics and immunoglobulin production of a subset of the human lymphoblas¬ toid cell lines of the present invention which produce monoclonal antibodies directed against HIV. Figure 4 is a graph showing the inhibition testing of monoclonal antibodies 120-16 and 71-31.
DETAILED DESCRIPTION OF THE INVENTION
All literature references and patents cited in thi specification are hereby incorporated by reference in thei entirety. The present inventors have isolated fourteen nove stable human lymphoblastoid cell lines producing monoclona antibodies directed against HIV encoded proteins. The an tibodies of the invention are useful in the prophylaxis of HI and in the diagnosis, and treatment of humans suffering fro HIV infections. These human monoclonal antibodies are directe against HIV protein gp41 and protein p24 (and the precursor and decomposition products of such proteins) . gp41 is a viral membrane glycoprotein expressed on th surface of infected cells and is a product of the env gene o HIV (as described in Essex, M., U.S. Patent No. 4,725,66 issued February 16, 1988). p24 is a viral core protein and i a product of the HIV σaσ gene (as described in Allan, J.S. e al., supr ) .
The human monoclonal antibodies of the present inven tion may be employed as the antibody component in the conven tional diagnostic assays of the type used to determine if patient has been exposed to, or infected with, HIV. Example below illustrates the use of the antibodies of the invention i a diagnostic assay. Administered to humans, the antibodies ca provide passive immunization of HIV-infected individuals. I addition, the antibodies of the invention can serve prophylac tically for administration to non-infected, high-risk in dividuals (such as health care workers who have been expose via a needle stick to HIV) . The antibodies of the inventi also can serve as research tools for epitope mapping of HI proteins gp41 and p24.
A particularly important use of the human monoclon antibodies of the present invention is for administration HIV infected expectant mothers. All of the antibodies of t present invention are of the IgG serotype (see below). Sin IgG's can pass through the placenta and reach the fetus utero, passive administration of the antibodies of the prese
invention to HIV-infected pregnant women would provide effec tive therapy for the fetus.
The human monoclonal antibodies may be conjugated t cytotoxic agents and used as imπtunotoxins (as described i Vitetta, E.S. et al.. Science 238: 1098-1104, 1987) or incor porated onto the surface of liposomes containing anti-HIV drug or toxins to specifically target such drugs or toxins t infected cells. As employed herein the term "immunotoxin" refers to a conjugate of an antibody with one or more toxins, drugs, radionuclides or cytotoxic agents. Among the cytotoxi agents that may be conjugated to the antibodies of the presen invention are ricin, diphtheria toxin and radionuclides. Rici is an extremely potent toxin produced by the beans of the plan Ricinus communis. In a typical treatment employing the huma monoclonal antibodies of the present invention as immunotoxins, the antibody (which binds to a protein that is expressed b HIV-infected cells) is conjugated to a toxin (e.g. ricin) tha is toxic to the HIV-infected cell (and to non-infected cells a well). By coupling the cytotoxic agent to the antibody, a hig level of toxic efficacy can be achieved against the target cel with a markedly lower level of non-specific toxicity. The us of the toxic agent is possible because the human monoclona antibodies to which the agent is coupled will carry the agen directly to the target (in this case, HIV-infected cells) thereby sparing non-infected cells from the toxin. Technique that may be employed to conjugate human monoclonal antibodies including those of the present invention, to cytotoxic agent are described in detail in Vitetta et al., supra and i European Patent Application Serial No. 279,668, publishe August 24, 1988 of Genentech, Inc..
The human lymphoblastoid cell lines (which produce th monoclonal antibodies of the present invention) were formed b immortalizing lymphocytes obtained from HIV-seropositiv patients by infecting such lymphocytes with Epstein Barr Viru (EBV) in vitro. Initially, blood was obtained from 58 HIV seropositive individuals, peripheral blood mononuclear cell were obtained and incubated overnight with EBV. The EB
infected cells were cultured at 80,000 cells per well i microtiter wells for 3-4 weeks and assayed for anti-HI antibody production using a non-commercial ELISA (see below and a commercial ELISA employing HIV-coated beads. Th specificity of each positive reaction obtained by the ELISA wa confirmed by testing for their non-reactivity on identica beads coated with bovine serum albumin (BSA) .
Approximately 9% of the lymphoblastoid cell culture tested positively in the non-commercial ELISA. After expansio the positive wells were cultured for two more weeks. It wa found that 2.4% tested positively for HIV proteins by ELISA an 0.67% proved to be specific for HIV by virtue of their non reactivity on the BSA beads. The anti-HIV antibodies produce were found to be directed against gp41 or p24 and had suffi cient avidity to show reactivity by ELISA, Western blot, radio immunoprecipitation and/or immunofluorescence. Therefore, al of these monoclonal antibodies would be useful in diagnosti assays for HIV. The stable clones were then subcultured 1 to times at 10 or 100 cells per well with irradiated huma lymphoblastoid feeder cells and expanded into tissue cultur flasks.
In a second round of immortalization/selection peripheral blood mononuclear cells from another 36 HIV seropositive individuals were obtained, immortalized by EB infection and assayed for anti-HIV production as above. Fou stable lymphoblastoid cell lines were obtained producin monoclonal antibodies: 120-16, 126-6, 126-50, 167-7 and 191- against gp41, and 134-F6 against p24.
In addition, one cell line, 98-4.3, producin monoclonal antibodies against p24, was obtained from positiv cultures derived from the first group of 58 patients describe above. The culture was subcultured twice after severa unsuccessful trials and is presently stable in culture.
The characteristics of the human monoclonal antibodie produced by the lymphoblastoid cell lines of the presen invention are described in Table III of Example 5 below.
The present inventors have performed some epito
mapping of the human monoclonal antibodies of the presen invention. For example, it can be seen from the data presente in Example 5, Table III below that monoclonal antibodies 50-6 and 98-43 bind to the same epitope cluster (i.e. amino acid falling between residues 579 and 613) Whereas 98-6 binds to t a different region (amino acids falling between residues 64 and 692). However, monoclonal antibodies 50-69 and 98-4 differ in their epitope specificity as demonstrated by the fac that 50-69 binds to peptide 599-613 whereas 98-43 binds t pepticle 579-604. Three of the anti-p24 antibodies have bee tested (i.e. 71-31, 91-5 and 91-6). All bind to the sam region of p24 (131-198).
All of the human monoclonal antibodies of the presen invention directed against gp41 (i.e. 50-69, 98-6, 98-43, 120 16, 126-6, 126-50, 167-7 and 191-3) mediated antibody dependen cellular cytotoxicity (ADCC) as shown in Table III below. Thi is a most important finding in that serotherapy (e.g. passiv immunization) and seroprophylaxis in animal retroviral model have been shown to be mediated by ADCC (Plata, F. et al.. Cel .48.* 231, 1987; Weinhold, K.J. et al, i. Natl. Cancer Inst. 75 717, 1985). The ADCC immune response is directed by specifi antibodies and involves mobilization of effector cell (cytotoxic T-cells, monocytes, and killer cells agains specific targets. It is believed that the ability to mount a ADCC response will be important for serotherapy an seroprophylaxis in HIV infections also.
The fourteen lymphoblastoid cell lines thus obtaine are stable in culture and produce human monoclonal antibodie directed against targets on HIV which are expressed in vivo i infected patients.
The human monoclonal antibodies of the present inven tion are all of the IgG serotype and may be recovered from th supernatants of monoclonal antibody producing lymphoblastoi cell cultures and purified by conventional methods known in th art for the purification of IgG. Such methods include Protein A Sepharose chromatography, a combination of Affigel Blue (Bio Rad, Richmond, CA) and Protein-A Sepharose chromatography, o
High Performance Liquid Chromatography (HPLC).
The eleven stable lymphoblastoid cell lines describe in Examples 1-6 below produce human monoclonal antibodies whic are directed against unique epitopes which are expressed i HIV-infected patients. Although some epitope mapping has bee performed (see Table III in Example 4 below), further epitop mapping will determine the exact specificity of each of th monoclonal antibodies and may reveal targets on the HIV gp4 and p24 protein molecules which can be candidates for vaccin production.
The human monoclonal antibodies of the present inven tion are directed against either immunodominant (common) o non-dominant epitopes of the gp41 and p24 viral proteins. employed in this specification, the term "immunodominant refers to an antigenic determinant that most patients respon by the production of antibodies. Antibodies 50-69 and 120-16 directed against gp41, are to immunodominant epitopes. Thes two antibodies may be employed for passive immunizations and/ diagnostic reagents. Antibodies 71-31 and 91-5, directe against p24, are to non-dominant epitopes.
Lymphoblastoid cell lines 91-5 and 120-16 (produci human monoclonal antibodies directed against p24 and gp4 respectively) have been deposited with the American Ty Culture (ATCC, Rockville, MD) and have received Accessi Numbers CRL 10038 and CRL 10037, respectively.
The classification of the antibodies of the inventi into an immunodominant or non-dominant grouping was a complished by inhibition testing as described in Example below. In this assay, sera collected from HIV serqpositi individuals were used to inhibit the binding of biotinylat monoclonal antibodies directed against HIV proteins to the respective antigens.
Of the monoclonal antibodies to p24 and gp41, on those to gp41 mediated antibody-dependent cellular cytotoxici (ADCC). In vitro cytotoxicity studies revealed that the mo active induced significant levels of killing was at minim concentrations of 15-250 ng Ab/ml. ADCC was assayed usi
peripheral blood mononuclear cells (MNC) as effectors and the CEM.NKR cell line, infected with HTLV-IIIB, MN and RF (viral strains) , as targets.
Two monoclonal antibodies to gp41 and one monoclonal antibody to p24 were purified and coupled to the deglycosylated A chain of ricin. The anti-p24 immunotoxin (IT) did not kill infected or uninfected H9 or U937 cells at concentrations up to 20 ug Ab/ml. IT made with monoclonal antibody to gp41, however, reduced protein synthesis in infected H9 cells by 50% (IC50) at concentrations of 500 ng/ml. The IC50 of anti-gp41 IT for infected U937 cells was 1000 ng/ml. In the presence of chloroquine, the IC50 of these immunotoxins (ITs) was 5-10 ng/ml.
When employed to treat individuals infected by HIV or suffering from AIDS, the human monoclonal antibodies of the present invention (having a specificity and a binding affinity for HIV proteins p24 and gp41) may be administered as passive immunization agents in effective amounts broadly ranging between about 200 mg and about 15 grams and preferably between 50 mg and 1 gram. The antibodies of the invention are adminis¬ tered parenterally, and preferably via the intravenous route. A typical treatment regimen would comprise administration of an effective amount of antibody administered over between about one week and about 6 months. The number of treatments required to control a patient's disease will vary from individual to individual, depending upon the severity and stage of the illness and the individual characteristics of each patient being treated. The total dose required for each treatment may be administered by multiple doses or in a single dose. The human monoclonal antibodies may be administered alone or in conjunction with other HIV treatments, such as AZT, in order to control a patient's disease. The anti-HIV treatment may be administered one or two times a week or more as determined by the patient's condition and the stage of the patient's disease. The human monoclonal antibodies of the present inven¬ tion can be incorporated into conventional pharmaceutical formulations for use in treating individuals that are afflicted
with HIV or for prophylaxis in individuals at risk for suc infections. The pharmaceutical formulations of the inventio comprising an anti-HIV effective amount, range between abou 200 mg and about 15 grams, of the human monoclonal antibodie of the present invention identified in Examples 1-4 below. Th quantity of effective dose applied by each injection i relatively unimportant since the total dosage can be reached b administration of one or a plurality of injections. In addi tion, such formulations may comprise pharmaceutically-accep table carriers, diluents, salts and other materials well-know in the art. Isotonic saline, sterile water, 10% maltose, huma serum albumin, glycine or other pharmaceutically-acceptabl materials may be used as diluents, carriers or solvents i preparing the pharmaceutical formulations comprising the huma monoclonal antibodies of the present invention.
The present invention is described below in specifi working examples which are intended to illustrate the inventio without limiting its scope.
EXAMPLE 1: IMMORTALIZATION OF HUMAN B-CELLS
Blood was obtained from 58 HIV-seropositive individual who were intravenous drug users or homosexuals. The presenc of antibody to HIV in the blood was determined using a commer cial enzyme-linked i munosorbent assay (ELISA) (Organon-Teknik Bio-Enzabead HTLV-III ELISA, Durham, NC) and confirmed b Western blot (Novapath Immunoblot Assay, Bio-Rad, Hercules, C and Biotech/DuPont, DuPont, Wilmington, DE). The diseas status of patients was established on the basis of an i munologic staging system as described by Zolla-Pazner et a (Proc. Nat. Acad. Sci. USA 84: 5404, 1987):
Scale Score T4/T8 ratio #T4/mm #lymphocytes/mm
0 > 1.0 > 500 > 1500
1 < 1.0 > 500 > 1500
2 < 1.0 < 500 > 1500
3 < 1.0 < 500 < 1500
Peripheral blood mononuclear cells collected from t 58 patients were obtained by centrifugation of hepariniz
blood, diluted 1:1 with RPMI-1640 and centrifuged on Histopaqu (Sigma, St. Louis, MO) at 300 x g for 30 minutes. Cells at th medium/Histopaque interface were recovered, washed three time and incubated overnight at a density of 2 x 10^ cells/ml wit the filtered supernatant from the EBV-transformed marmoset cel line B95-8 (Proc. Nat. Acad. Sci. USA 70: 190, 1973, availabl under Accession Number CRL 1612 from the American Type Cultur Collection, ATCC, Rockville, MD). Lymphocytes were then washe once and cultured in RPMI-1640 medium (M.A. Bioproducts, Walkersville, MD) supplemented with 10% fetal calf seru (Hyclone Labs, Logan, UT) 2mM L-glutamine, lOOU/ml penicillin, and 100 micrograms/ml streptomycin (complete medium) for fou weeks in 96-well plates (Costar, Cambridge, MA) at 80,000 cell per well.
EXAMPLE 2: ISOLATION AND SCREENING OF LYMPHOBLASTOID
CELL LINES FOR ANTI-HIV ANTIBODY PRODUCTION After screening for anti-HIV antibody production by non-commercial ELISA (see below), positive cultures wer expanded into wells of 24-well tissue culture plates (Costar) and cultured for two more weeks. All initial and expande cultures were fed at weekly intervals with complete medium. Cultures with supernatants showing specific reactivity to HI were then subcultured one to two times at doubling dilution o feeder layers of irradiated GK-5 human lymphoblastoid cell
(derived from a variant of GM1500; Satoh, J. et al., _j_ Engl
J. Med. 309: 217, 1983) which had been exposed to 3000 Rads o gamma-radiation. Stable clones were then subcultured one t three times at 10 to 100 cells per well on feeder cells an then expanded into flasks.
Thus, initial cultures of immortalized B-cell (hereinafter referred to as lymphoblastoid cell lines) wer established and further characterized as described below.
The screening of the initial cultures in 96-well plate was performed using a non-commercial ELISA. Immulon 2 plate
(Dynatech, Chantilly, VI) were coated overnight at 4°C with micrograms/ml of HTLV-IIIB lysate (purchased from Electro Nucleonics, Inc., Silver Spring, MD) diluted in carbonat buffer, pH 9.8. Plates were washed three times with phosphat buffered saline, pH 7.2, containing 0.05% Tween 20 (PBS-Tween) The culture supernatants to be assayed (0.1 ml per well) wer then added and incubated for 90 minutes at 37°C. Subsequently plates were washed with PBS-Tween and incubated with goat anti human immunoglobulin conjugated to alkaline phosphatas (Organon Teknika-Cappel, Malvern, PA) for another 90 minutes a 37°C. The plates were washed again with PBS-Tween and th substrate, p-nitrophenyl phosphate in 10% diethanolamine, wa added for 30 minutes. The reaction was terminated with 2 microliters of IN NaOH and the absorbance was read at 405 nm i an automated ELISA reader (MR 600 Microplate Reader, Dynatech)
The specificity of the antibody binding was assessed b testing the supernatants for reactivity against HIV-coate beads (Bio-EnzaBead) and against uncoated beads (obtained fro
Organon Teknika Cappel) which were then coated with bovin serum albumin (BSA, Sigma Chemical Co. ) by incubating the bead in 1.25% BSA diluted in PBS for 1 hour at room temperature Reactivity with HIV-coated beads, but not with BSA-coate beads, was used as a criterion for specificity. Furthe analysis of the specificity of the monoclonal antibodies wa then carried out by Western blot using a commercially-availabl kit (Bio-Rad, Richmond, CA) and by radioimmunoprecipitatio (RIP). RIP assays were carried out using the method of Pinte and Honnen {d _ Immunol. Methods, in press). Briefly, 3 micrograms of HTLV-IIIB lysate (purchased from Organon
125 Teknika), was labeled with [I] using the Bolton-Hunte reagent (New England Nuclear, Boston, MA) . Bound label wa separated from free label on a Bio-Gel P-4 column (Bio-Rad)
Fifty microliters of culture supernatant were incubated with x 10^ cpm of the labeled lysate for 1 hour at 37°C, then 5 microliters of 10% fixed Staphlococcus aureus (Pansorbi
Calbiochem, La Jolla, CA) was added. The immunoprecipitate w washed three times by centrifugation and the air-dried pell
was resuspended in buffer, boiled for 3 minutes an electrophoresed on a 10% SDS polyacrylamide gel. The gels wer dried and exposed for one to three days to X-Omat S fil (Kodak, Rochester, NY) . The class and light chain type of anti-HIV antibody was determined by ELISA. For these assays, microtiter plates (Immulon 2) were coated with 4 micrograms/ml of HIV lysate (Electro-Nucleonics) and then incubated with culture super¬ natants. The type of antibody binding to HIV was determine using the following alkaline phosphatase-coupled antibodies: goat anti-human IgG (gamma specific), goat anti-human kapp chain and goat anti-human lambda chain (Organon Teknika-Cappel, Malvern, PA) . The subtype of the monoclonal antibody was als analyzed by ELISA using alkaline phosphatase-labeled mouse monoclonal antibodies against the four subclasses of human Ig (Zymed, San Francisco, CA) .
Immunoglobulin quantitation was also performed b ELISA. Immulon 2 plates were coated with goat anti-human Ig (gamma specific) and incubated with culture supernatants. Bound IgG was detected with alkaline phosphatase-labeled goa anti-human IgG (gamma specific). Affinity-purified human Ig (Cappel) was used to produce standard curves.
A total of 14,329 cultures in microtitre wells wer established using cells derived from the 58 subjects. Ap proximately half of these cultures were derived from thre serial bleeds from a single subject (with a scale score of 1) over a period of three months. The remaining wells wer established using cells derived from 57 subjects whose scal scores ranged from 0 to 3. The results of this procedure ar shown in Table I below.
TABLE I
QUANTITATIVE RESULTS OF THE PROCEDURE USED TO
PRODUCE HUMAN MONOCLONAL ANTIBODIES TO HIV
No. of % positiv wells wells
Infection of PBMC with EBV 14,329 (100)
4 weeks
V Screen for anti-HIV by Non-commercial ELISA 1,290 9.0
Expand positive wells
2 weeks
V Screen for anti-HIV by: Non-commercial ELISA 573 4 . 0
Commercial ELISA 340 2 .4
Screen for specificity (reactive HIV, unreactive with BSA) 97 0.67
Screen for reactivity by RIP 57 0.40
Subculture positive wells by doubling dilution (10,000-10 cells/well)
4-6 weeks
V
Screen by commercial ELISA 16* 0.11*
Subculture positive wells at (100 and 10 cells/well)
4-6 weeks
V
Screen by commercial ELISA 0.05*
No. and % of positive plates from subcultures of individu wells which contain at least one antibody positive well.
After four weeks, 9% of the wells displayed antibody production as revealed by the non-commercial ELISA (Table II). After expansion, only 2.4% of the original cultures continued to produce antibody reactive with a commercial ELISA kit and only one-quarter of these (0.67% of the original 14,329 cultures) were producing antibodies which reacted specifically with HIV.
To determine whether the severity of disease in the cell donor affected the number of cultures able to produce antibodies and the specificity of antibody produced, the seropositive cell donors were categorized with respect to disease status using the immunologic staging system of Zolla- Pazner et al. (supra) and the results are shown in Table II below.
TABLE II
CHARACTERISTICS OF CELL CULTURES DERIVED FROM PATIENTS AT DIFFERENT STAGES OF HIV INFECTION
No. of positive wells No. of
(Includes wells HIV-specific with HIV- No. of
Scale No. of No. of & non-specific specific clumps
Score patients wells reactivity) antibody5 per well
HIV-seronegative patients:
3 637 0 0 7.3
HIV-seropositive patients:
0 4 725 18 (2.4%) 6 (0.8%) 0.92
1 13 8,789 180 (2%) 66 (0.7%) 0.88
2 20 2,792 54 (1.9%) 16 (0.5%) 0.65
3 21 2,023 88 (4.3%) 9 (0.4%) 0.22
58 14,329 340 2.4% 97 0.67% 0.66
* Specificity of anti-HIV antibodies were assessed by commer cial ELISA using HIV-coated and BSA-coated beads.' + B cells transformed by EBV stick together and creat characteristic clumps of cells which were quantitate microscopically.
The results, shown in Table II, revealed that culture obtained from patients with a scale score of 3 (severe im munodeficiency) gave a higher percentage of antibody producin wells than patients with lesser scale scores. However, onl 10% (9/88) of reactive wells from the cells of stage 3 patient were specifically reactive with HIV whereas 30-37% of well from cells of patients with scale scores of 0-2 were specifi cally reactive with HIV. Thus, after six weeks of culture, cells from patients with lower scale scores produced a highe percentage of wells containing HIV-specific antibody.
Analysis of antibodies from ELISA-positive expande cultures was carried out by RIP. Only 59% of supernatants fro these cultures were also positive on RIP analysis. RI analysis demonstrated that, out of 57 supernatants, 44 showe reactivity to env-encoded proteins, 11 to gag proteins and 2 t reverse transcriptase.
Therefore, specific lymphoblastoid cell lines wer isolated and further cloned as described below.
EXAMPLE 3: SPECIFICITY AND REACTIVITY OF THE HUMAN MONOCLONA
ANTIBODIES OF A SUBSET OF THE PRESENT INVENTION
The 57 cell lines mentioned above were then cloned b doubling dilution from 10,000 to 10 cells per well. Wells wit the lowest cell concentration which were producing antibodie were then picked and cloned at 100 or 10 cells per well. Usin this procedure, seven cell lines, 3 producing anti-gp4 antibodies and 4 producing anti-p24 antibodies were establishe which have been cloned from one to three times at 100 or 1 cells per well. The reactivities of the antibodies from thes lines are shown in Figures 1 and 2.
All seven of the cell lines of this Example produce antibodies of the IgG subtype as shown in Figure 1. In Figur 1, all lines received [ 125I]-labeled HIV lysate reacted wit lane 1, serum from an HIV-infected subject, lane 2, wit antibody from cell line 50-69, lane 3, with antibody from cel line 98-6, lane 4, with antibody from cell line 98-43, lane 5 with antibody from cell line 71-31 lane 6, with antibody fro
cell 91-5, lane 7, with antibody from cell and line 91-6 an lane 8, with antibody from 98-4.9. The molecular weights o the major viral proteins are shown on the left in kilodaltons. Antibody from three of the cell lines bound to ejήv-encode protein gp41 (lines 50-69, 98-6 and 98-43, lanes 2-4 respec tively) . Antibodies from four of the cell lines bound to ga encoded protein p24 (lines 71-31, 91-5, 91-6 and 98-4.9, lane 5-7 respectively). By RIP, antibodies from cell lines 71-31, 91-5 and 91-6 reacted with p24. Antibodies from 98-4.9 wer unreactive by RIP since IgG3, the subtype of this antibody, does not bind to Protein A and is therefore not precipitated. Antibody from all 3 of these anti-gag cell lines were als tested by Western blot (Figure 2).
In Figure 2, Western Blot strips were used to show th reactivity of serum from a normal control (lane 1) , an HIV infected subject (lane 2), and of supernatant from cell line 71-31 (lane 3), 91-51 (lane 4), 91-6 (lane 5), and 98-4.9 (lan 6) . Western blot analysis showed all 3 monoclonal antibodie reacted with p24 and with known gag precursors p55 and p40 All four antibodies also reacted with a breakdown product o p24 which migrated with a mobility of approximately 22 kilodal tons (kd) ; three of the four anti-gag monoclonal antibodie also reacted with additional intermediate precursors which wer noted with a mouse monoclonal antibody and which had mobilit of approximately 37, 31 and 28 kd.
Studies of the growth characteristics and level o antibody production of each line was performed. Each cell lin was initially cultured in replicate wells at 0.5 x 10^ cells/m for 1-8 days. The number of cells and the amount of im munoglobulin produced is shown in Figure 3. In Figure 3, a each time point, separate wells were used to test for viabl cell number (closed circles) and for secreted human IgG (ope circles). Cell lines studied were 50-69(a), 98.6(b), 98-43(c) 71-31(d), 91-5(e), 91-6(f) and 98-4.9(g). Peak cell density was noted at 4 days with maximu densities of 1.0 to 2.4 x 10° cells/ml. The doubling time o cells in log phase ranged from 40-61 hours. The concentratio
of immunoglobulin produced varied widely, generally peaking at day 5 of culture and ranging from 9-112 micrograms/ml.
It should be noted that cell line 98-4.9 recently lost the ability to produce human monoclonal antibodies.
EXAMPLE 4: GENERATION OF ADDITIONAL LYMPHOBLASTOID CELL LINES
PRODUCING HUMAN MONOCLONAL ANTIBODIES TO HIV
Peripheral blood mononuclear cells were obtained from another 39 HIV-seropositive individuals, the cells immortalized by EBV infection, screened and selected as in Examples 1-3 above. Positive cultures were expanded, subcultured by doubling dilution and again subcultured one to three times at 10 to 100 cells per well. Four stable lymphoblastoid cell lines producing human monoclonal antibodies were obtained as follows: 120-16, 126-6 and 126-50 directed against gp41; and 134-F6 directed against p24.
Each of the monoclonal antibodies of this Example were tested for their specificities by means of commercial ELISA (the supernatants were reactive with HIV-coated beads and unreactive with BSA-coated beads), by radioimmunoprecipitation and by Western Blot as in Example 3 above. The characteristics of these human monoclonal antibodies are shown in Table III below.
EXAMPLE 5: CHARACTERIZATION OF THE HUMAN MONOCLONAL
ANTIBODIES OF THE PRESENT INVENTION The specificity and biological activities of the human monoclonal antibodies of the present invention are summarized in Table III below.
TABLE III Characteristics of human monoclonal antibodies against HIV
Cell line Isotype, RIP ELISA Western Blot Function Approx.
Subclass ENV9 PE3 pl21 r-gp41 r-p24 Neutr. Enhanc. ADCC Epitope Region and Light
8 Chain Type
50-69 IgG2k1 gp41 + + - _ - + 599 - 6132,a
98-6 IgG2k gp41 + + - - - + 642 - 692
98-43 IgG2k gp41 + + - - - + 579 - 6042 120-16 IgG2k gp41 + NT3 - - + + NT 126-6 IgG2k gp41 + NT - - - + 567 - 649 126-50 IgG2k gp41 + NT - - - + 567 - 649 167-7 igGii gp41 NT NT NT NT NT NT NT NT 661 - 683 194-1 IgGjl gp41 NT NT NT NT NT NT NT NT NT
71-31 gGii4 p24 NT + - - - 131 - 1985
91-5 igGxi p24 NT + - - - 131 - 198
91-6 IgGjl p24 NT + - - - 131 - 198
CM 98-4. ≠ IgG3l p24 NT NT - - - NT
98-4.3 igGii p24 NT NT NT NT NT NT NT NT NT 134-F6 IgG3k p24 NT NT NT NT NT NT NT NT NT
* k = Kappa
2 The Modrow numbering system according to i. Virol. 61: 570, 1987.
3 NT = Not tested
4 1 = Lambda
5 The numbering system according to Wain-Hobson, et al., Cell 40; 9, 1985
O 00 ON 6 This lymphoblastoid cell line has not been stabilized with respect to the production of monoclonal antibodies e a Tested for reactivity on LABSYSTEMS kit
I
In Table III, epitope mapping was performed usin recombinant antigens using a Western Blot format. Vira Neutralization and enhancement assays were performed as in J Clin. Micro. 26: 231, 1988. ADCC assays were performe according to Lyerly, H.K. et al. AIDS and Human Retroviruse 3.: 409-422, 1987. Western Blot analysis was performed usin recombinant p24 or gp41 (supplied by Organon-Teknica) .
Elisa's were performed using cloned gp41 antigens ENV9 is a cloned gp41 protein encompassing residues 461 to 76 (obtained from DuPont, Wilmington, DE). PE3 is a 286 amin acid sequence from gpl20 (obtained from DuPont, Wilmington DE). pl21 contains residues 561-649 of gp41 (obtained fro Centocor, Malvern, PA) .
As can be seen in Table III above, all of the anti-gp4 human monoclonal antibodies of the present invention were o the IgG serotype and mediated antibody dependent cellula cytotoxicity (ADCC).
In addition, epitope mapping showed that five of th anti-gp41 antibodies bound to different epitopes on the vira protein. Monoclonal antibody 50-69 bound to residues 599-613 monoclonal antibody 98-6 was directed against a peptid encompassing residues 642-692; monoclonal antibody 98-43 boun to a peptide encompassing gp41 residues 579-604; monoclona antibody 120-16 bound residues 644-663; and monoclonal antibod 116-7 bound to residues 661-683. The numbering system for th gp41 peptide is according to J . Virol. 61: 570, 1987.
All three of the anti-p24 monoclonal antibodies teste (71-31, 91-5 and 91-6) bound to a HIV p24 peptide encompassin residues (131-198 (the numbering system according to Wain Hobson et al. Cell 40: 9, 1987) (Table III).
Finally, none of the monoclonal antibodies of th present invention were able to neutralize the infectivity o HIV and one (120-16) enhanced viral pathogenicity.
EXAMPLE 6: INHIBITION TESTING OF THE MONOCLONAL
ANTIBODIES OF THE PRESENT INVENTION Presented below is an example of the use of th
monoclonal antibodies of the present invention in a diagnostic assay for HIV.
Immulon 2 plates (Dynatech) were coated with 0.5 micrograms/well of an HIV lysate diluted in 0.05M bicarbonate buffer, pH 9.6 for 2 hours at 37βC, and overnight at 4°C. After washing the plates with phosphate buffered saline, pH 7.4, containing 0.05% Tween (PBS-Tween), samples of human sera, obtained from HIV seropositive or seronegative individuals were added to each well at 0.5 micrograms/well, diluted 1:10 to 1:1000. The plates were incubated at room temperature over¬ night and washed three times with PBS-Tween. A predetermine dilution of biotinylated monoclonal anti-HIV antibodies (see below) was then added in a volume of 100 microliters and the plates incubated for 2 hours at 37°C. The wells were washe three times with PBS-Tween and the reaction developed by addin an avidin-biotinylated-horseradish peroxidase complex (Vecto Labs) and incubated for 2 hours at 37βC. After washing 5 time with PBS-Tween, 2,2'-azino-di-[3-ethylbenzthiazoline sulfonate] (ABTS) was added as substrate and incubated for 30 minutes a room temperature. The optical density of each well was read i an ELISA reader at 410nm.
Biotinylation of the monoclonal antibodies to HIV wa performed as follows. Each monoclonal antibody was partiall purified by ammonium sulfate precipitation and/or chromatog raphy on Protein A-Sepharose. After dialysis against 0.1 sodium bicarbonate 75 microliters of N-hydroxyl-suc cinimidobiotin (5 mg in 1 ml of DMSO) was added to 1 ml of th antibody at a concentration of 5 mg/ml. The reaction wa allowed to proceed at room temperature with shaking for 3 hour and then dialyzed against phosphate buffered saline, pH 7.4 The biotinylated monoclonal antibodies were stored at -25°C i 50% glycerine before use.
The results of the inhibition tests are shown in Figur 4. In Figure 4, the seronegative sera is designated (-) an the seropositive (+).
The data presented in Figure 4 shows that antibodie 120-16 and 71-31 are directed against immunodominant epitope
and non-dominant epitopes respectively. Thus, seropositive sera are able to compete for the binding of labeled antibody 120-16 to the HIV lysate defining the epitope of this monoclonal antibody as immunodominant. Non-dominance was established for the epitope with which 71-31 reacts as a result of the inability of most seropositive sera to compete with this antibody for binding to the HIV lysate.
Claims (21)
- WHAT IS CLAIMED IS: 1. A human monoclonal antibody directed against human immunodeficiency virus protein p24.
- 2. The human monoclonal antibody of claim 1, wherei said antibody is of the IgG serotype.
- 3. A human lymphoblastoid cell line producing a huma monoclonal antibody directed against human immunodeficienc virus protein p24.
- 4. The human lymphoblastoid cell line of claim derived from a human infected with human immunodeficienc virus.
- 5. A method for treating a mammal infected with huma immunodeficiency virus comprising administering to a mammal i need of such treatment an effective amount of a human monoclo nal antibody directed against HIV protein p24 and a phar maceutically-acceptable carrier.
- 6. The method of claim 5 wherein - said effectiv amount ranges between about 200 mg and 15 grams
- 7. The method of claim 5 comprising administerin said monoclonal antibody parenterally.
- 8. A pharmaceutical formulation for treating mammal infected with human immunodeficiency virus comprising a effective amount of a human monoclonal antibody directe against HIV protein p24.
- 9. The pharmaceutical formulation of claim 8 furthe comprising a pharmaceutically-acceptable carrier.
- 10. A human monoclonal antibody directed against huma immunodeficiency virus protein gp41, said monoclonal antibod having the ability to mediate antibody dependent cellular cytotoxicity.
- 11. The monoclonal antibody of claim 10 wherein said monoclonal antibody is of the IgG serotype.
- 12. A human lymphoblastoid cell line producing a human monoclonal antibody directed against human immunodeficiency virus protein gp41.
- 13. The human lymphoblastoid cell line of claim 12 derived from a human infected with human immunodeficiency virus.
- 14. A method for treating a mammal infected with human immunodeficiency virus comprising administering to a mammal in need of such treatment an effective amount of a human monoclo- nal antibody directed against HIV protein gp41, said monoclonal antibody having the ability to mediate antibody dependent cellular cytotoxicity.
- 15. The method of claim 14 wherein said antibody is of the IgG serotype.
- 16. The method of claim 14 wherein said effective amount ranges between about 200 mg and 15 grams
- 17. The method of claim 16 comprising administering said monoclonal antibody parenterally.
- 18. A pharmaceutical formulation for treating mammals infected with human immunodeficiency virus comprising an effective amount of a human monoclonal antibody directed against HIV protein gp41, said human monoclonal antibody having the ability to mediate antibody dependent cellular toxicity.
- 19. The pharmaceutical formulation of claim 18 further comprising a pharmaceutically-acceptable carrier.
- 20. A human monoclonal antibody having the charac- teristics of the monoclonal antibody produced by ATCC Accessio No. 10038.
- 21. A human monoclonal antibody having the charac- teristics of the monoclonal antibody produced by ATCC Accessio No. 10037.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31674489A | 1989-02-28 | 1989-02-28 | |
US316744 | 1989-02-28 | ||
US40998689A | 1989-09-19 | 1989-09-19 | |
US409986 | 1989-09-19 | ||
PCT/US1990/001132 WO1990009805A1 (en) | 1989-02-28 | 1990-02-28 | Human monoclonal antibodies to human immunodeficiency virus |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU52256/93A Division AU680836B2 (en) | 1989-02-28 | 1993-12-08 | Human monoclonal antibodies to human immunodeficiency virus |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5188590A true AU5188590A (en) | 1990-09-26 |
AU651794B2 AU651794B2 (en) | 1994-08-04 |
Family
ID=26980569
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU51885/90A Ceased AU651794B2 (en) | 1989-02-28 | 1990-02-28 | Human monoclonal antibodies to human immunodeficiency virus |
AU52256/93A Ceased AU680836B2 (en) | 1989-02-28 | 1993-12-08 | Human monoclonal antibodies to human immunodeficiency virus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU52256/93A Ceased AU680836B2 (en) | 1989-02-28 | 1993-12-08 | Human monoclonal antibodies to human immunodeficiency virus |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0418347A4 (en) |
JP (1) | JPH04505099A (en) |
AU (2) | AU651794B2 (en) |
CA (1) | CA2028121A1 (en) |
WO (1) | WO1990009805A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413515B1 (en) | 1996-03-12 | 2002-07-02 | Ovogenix Immunpharma Gmbh | Avian, vitelline antibodies directed against HIV antigens |
DE19809785C2 (en) * | 1998-03-08 | 2000-02-10 | Wolfgang Bergter | Radioimmune drug for the treatment of HIV-1 infection |
FR2777285B1 (en) * | 1998-04-10 | 2000-05-19 | Bio Merieux | PEPTIDE LIGAND WITH SPECIFIC AFFINITY TO HIV-1 RETROVIRUS P24 PROTEIN |
US7744887B2 (en) | 2004-06-01 | 2010-06-29 | Merck & Co., Inc. | Human antibodies interacting with HIV gp41 |
CA3045756A1 (en) | 2015-12-05 | 2017-06-08 | Centre Hospitalier Universitaire Vaudois | Hiv binding agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR930000189B1 (en) * | 1984-10-18 | 1993-01-11 | 앵스뛰띠 빠스뙤르 | Envelope antigens of lymphadenopathy associated virus |
DK169582B1 (en) * | 1986-06-23 | 1994-12-12 | Squibb Bristol Myers Co | Human monoclonal antibody capable of reacting with an epitope on the LAV / HTLV-III envelope glycoprotein gp41, cell lines producing such antibody, pharmaceutical preparation containing the antibody, and method for determining the presence of LAV / HTLV-III in a biological sample. and method for separating specific antigenic determinants of LAV / HTLV-III using ant |
-
1990
- 1990-02-28 AU AU51885/90A patent/AU651794B2/en not_active Ceased
- 1990-02-28 CA CA002028121A patent/CA2028121A1/en not_active Abandoned
- 1990-02-28 EP EP90904509A patent/EP0418347A4/en not_active Withdrawn
- 1990-02-28 JP JP2504472A patent/JPH04505099A/en active Pending
- 1990-02-28 WO PCT/US1990/001132 patent/WO1990009805A1/en not_active Application Discontinuation
-
1993
- 1993-12-08 AU AU52256/93A patent/AU680836B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU651794B2 (en) | 1994-08-04 |
CA2028121A1 (en) | 1990-08-29 |
EP0418347A1 (en) | 1991-03-27 |
JPH04505099A (en) | 1992-09-10 |
EP0418347A4 (en) | 1994-12-14 |
AU5225693A (en) | 1994-03-03 |
WO1990009805A1 (en) | 1990-09-07 |
AU680836B2 (en) | 1997-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gorny et al. | Generation of human monoclonal antibodies to human immunodeficiency virus. | |
EP0459779B1 (en) | Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type I (HIV-1) GP120 and methods of use | |
EP0308936B1 (en) | Antibody heteroconjugates for the killing of HIV-infected cells | |
Fung et al. | Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 | |
ROBINSON et al. | Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines | |
US5807992A (en) | HIV-2 transmembrane glycoprotein homodimer (gp 80) | |
US5854400A (en) | Monoclonal antibodies which neutralize HIV-1 infection | |
Cavacini et al. | Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals | |
JP2626680B2 (en) | Human monoclonal antibody against lymph node damage related virus | |
US5459060A (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) | |
US5695927A (en) | Monoclonal antibodies specific for HIV and the hybridomas for production thereof | |
WO1990010457A1 (en) | Method of treating hiv infections using immunotoxins | |
US5731189A (en) | Human monoclonal antibodies to human immunodeficiency virus | |
US6008044A (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC) | |
US6241986B1 (en) | Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV | |
Cotropia et al. | A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates | |
AU651794B2 (en) | Human monoclonal antibodies to human immunodeficiency virus | |
CA2058630A1 (en) | Human monoclonal antibodies to hiv-1 mn gp 120 | |
US6083504A (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1) | |
Lake et al. | Generation and characterization of a human monoclonal antibody that neutralizes diverse HIV-1 isolates in vitro | |
US5798251A (en) | Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120 | |
WO1991006575A1 (en) | Hiv-1 specific human monoclonal antibody | |
EP0400245B1 (en) | Proteins and glycoproteins of the HIV-2 EHO retrovirus antibodies directed against them - application for the diagnosis | |
FÉVRIER et al. | Two new human monoclonal antibodies against HIV type 1 glycoprotein 120: characterization and neutralizing activities against HIV type 1 strains |